How much funding has Saluda raised?

Saluda has raised $375.0M in total funding, most recently a Growth Equity round.

Who are Saluda's investors?

Saluda's investors include Wellington Management, Redmile Group, Boston Scientific Corporation, Action Potential Venture Capital, Bioscience Managers, TPG Life Sciences Innovation.

Where is Saluda headquartered?

Saluda is headquartered in Macquarie Park, Australia.

What industry is Saluda in?

Saluda operates in Biotech, Healthcare.

Saluda

IPO

Homepage - Saluda Medical US

Macquarie Park, Australia · Founded 2011 · $375.0M raised

Biotech

Healthcare

Headquarters: Macquarie Park
Founded: 2011
Business Model: B2B
Website: saludamedical.com

Total Funding: $375.0M
Last Round: $100.0M Growth EquityJan 2025
Rounds: 5

About

Saluda Medical develops the Evoke® System, the world's first closed-loop spinal cord stimulation (SCS) platform for chronic pain treatment. Founded in 2011 in Australia, the company pioneered Evoked Compound Action Potential (ECAP) sensing technology that objectively measures the spinal cord's neural response to stimulation and automatically adjusts therapy on every pulse — replacing open-loop guesswork with precise, biomarker-driven neuromodulation. The Evoke System received FDA premarket approval in 2022 and the EVA automated programming platform launched in the US in 2025. With over $664M raised and clinical results published in The Lancet Neurology and JAMA Neurology, Saluda is redefining the standard of care for intractable chronic pain of the trunk and limbs.

Summary

Saluda is a Biotech company based in Macquarie Park, Australia, founded in 2011. It has raised $375.0M in total across 5 rounds, most recently a $100.0M Growth Equity round in Jan 2025. Investors include Wellington Management, Redmile Group and Boston Scientific Corporation.